Autolus presents positive obe-cel data
Analysis based on 6 articles · First reported May 21, 2026 · Last updated May 21, 2026
The positive clinical data presented by Autolus Therapeutics for its obe-cel therapy could lead to increased investor confidence and a potential rise in the company's stock price. This development is significant for the biotechnology and pharmaceutical industries, highlighting advancements in cancer treatment.
Autolus Therapeutics plc announced the online publication of an abstract for the American Society of Clinical Oncology (ASCO) Annual Meeting, where it will present clinical data on its obe-cel therapy. The data, from a post-hoc analysis of the Phase Ib/II FELIX study, shows an overall response rate of 59% and a median duration of response of 42.6 months for patients with B-cell acute lymphoblastic leukemia (B-ALL) and extramedullary disease (EMD). Matthias Will, Chief Development Officer of Autolus Therapeutics, highlighted obe-cel as a potential treatment option for this difficult-to-treat patient population. Jae Park from Memorial Sloan Kettering Cancer Center will present the abstract at the ASCO meeting on May 30, 2026. These findings suggest a positive benefit-risk profile for obe-cel.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard